Portola

Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress

...UTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- portola Pharmaceuticals, Inc. today announced several scie...clinical development, as well as a presentation by portola co-founder David Phillips on new directions in ant...botic drug discovery. In the past six months, portola has announced global development and commercializa...

Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update

...TH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- portola Pharmaceuticals, Inc. today announced that it will...reduced potential for drug-drug interactions. portola is currently conducting EXPLORE-Xa, a Phase II dos...ts with acute coronary syndrome (ACS). About portola Pharmaceuticals, Inc. ...

Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel

... -- portola to Receive $75 Million Upfront Cash Payment, $500 ...UTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- portola Pharmaceuticals, Inc., a privately-held biopharmac...ent, Novartis will make an upfront cash payment to portola of $75 million....

Medical Experts Use Data to Dispel Myths About Fad Diets and Exercise

...ity and Stanford . He has been a professor of medicine, as well as having worked in private practice, for over thirty years. The Beebes live in portola Valley, just south of San Francisco, and have four children and eight grandchildren. iUniverse is the premier book publisher for emerging, s...

YoNaturals to Install Healthy Vending Machines at Stanford University

...oNaturals involves providing the University with multiple 'YoZone' vending machines through YoNaturals' exclusive area distributor, Natural Now LLC of portola Valley, Ca. The machines will be placed in various buildings throughout the campus, and as an added perk, the departments selected to house these mach...

Synergy Life Science Partners Closes $143M Debut Medical Device Fund

... portola VALLEY, Calif., Jan. 9 /PRNewswire/ -- Synergy Life Science Partners, LP, a...ling, Synergy Life Science Partners, LP, is a venture capital fund based in portola Valley, CA that invests directly in private, early-stage medical device fir...

An Innovation in Health Care Opens at CVS/pharmacy Stores in Los Angeles Metro Area

... Aliso Creek Rd. - Anaheim, 1660 West Katella Ave. - Buena Park, 8850 Valley View St. - Costa Mesa, 1150 Baker St. - Foothill Ranch, 26686 portola Pkwy. - Huntington Beach, 19121 Beach Blvd. - Irvine, 14330 Culver Drive - Ladera Ranch, 27702 Crown Valley Pkwy. - San Clemente, 638 Cami...

Portola in Medical Technology

Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention

... and efficacy information for further studies that portola may conduct in acute coronary syndromes, secondary...to grow to over $14 billion by 2020. About portola Pharmaceuticals, Inc. portola Pharmaceuticals develops innovative therapeutics b...

Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders

...o prevent thrombosis and subsequent heart attacks. portola believes that PRT060128 may provide significant cl...d predictable, dose-dependent platelet inhibition. portola expects to begin patient enrollment in an 800 pati...entions (PCI) before the end of this year. About portola Pharmaceuticals, Inc. ...

Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008

...el et al Time: 9:00 a.m. - 5:00 p.m. Hall A-B1, Poster Board C6 About portola Pharmaceuticals, Inc. portola Pharmaceuticals develops innovative therapeutics based on targets with esta...

Portola Completes $60 Million Financing to Advance Its Therapeutic Programs

...ical Candidates Address Global Thrombosis Market portola is advancing two differentiated drug candidates th...ffects compared to other targets such as thrombin. portola believes betrixaban will offer several advantages ... does not require monitoring or dose adjustment. portola has successfully completed a Phase 2 trial demonst...

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

...udy and achieved high-level platelet inhibition. portola presented the data in a poster session titled "Fir...rsible platelet inhibition in the chronic setting. portola has studied this compound in a robust Phase I clin...ion. Based on positive results from these studies, portola intends to initiate its Phase II program in 2007. ...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

...replacement (TKR) surgery. Based on these results, portola will advance PRT054021 into further clinical testi...ent and is the result of many years of work by the portola team in the field of anticoagulants," said Charles...erties compared to other targets such as thrombin. portola believes its oral Factor Xa inhibitor will offer s...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

.... CEST in the exhibition area. In addition, portola will make the following presentations: "Ini...erties compared to other targets such as thrombin. portola believes its oral Factor Xa inhibitor will offer s...rsible platelet inhibition in the chronic setting. portola has studied this compound in a robust Phase I clin...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

...s undergoing total knee replacement (TKR) surgery. portola expects to move PRT054021 into Phase III clinical ...aited a new generation of oral anticoagulants, and portola has a promising compound with compelling drug char...erties compared to other targets such as thrombin. portola believes its oral Factor Xa inhibitor will offer s...

Portola in Biological Technology

Spectros T-Stat Tissue Oximeter Clinical Studies Presented at PAS (Pediatric Academic Societies') Conference

... portola VALLEY, Calif., May 19 /PRNewswire/ -- Spectros announced today that its T-Stat Tissue Oximeter was featured in two presentations at the Pediatric Aca...

Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific

... portola VALLEY, Calif., May 6 /PRNewswire/ -- Spectros Corporation (Portola Valley, CA) filed in Federal District Court today against Thermo Fisher Scientific...

Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting

...:30 PM Hall A (Moscone Center) About portola Pharmaceuticals, Inc. portola Pharmaceuticals develops innovative therapeutics b...la.com . Contact: Mardi Dier - CFO, portola Pharmaceuticals 650-246-7236 mdier@port...

Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation

...fer advantages over other anticoagulation targets. portola believes betrixaban will offer several key differe... Xa inhibitors in development and with warfarin. portola has completed EXPERT, a 200-patient Phase II trial...n is well tolerated over a range of dose levels. portola may develop betrixaban for additional indications ...

Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations

...n Finance from the University of Maryland. About portola Pharmaceuticals, Inc. portola Pharmaceuticals, Inc. is a privately-held biopharm...econdary prevention of MI and stroke. In addition, portola has a robust preclinical pipeline targeting opport...

Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%

... portola VALLEY, Calif., March 31 /PRNewswire/ -- Spectros Corporation (Portola Valley, CA) reported that 2007 year-over-year sales rose 36%, reflecting growin...

Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics

...gh clinical execution of large multinational Phase III clinical trials. Prior to joining Nile, Dr. Lieu served as Director of Clinical Development for portola Pharmaceuticals, Inc., where he led the global development of a large ADP antagonist program in acute coronary syndrome. In this role, Dr. Lieu was re...

Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic

...ldwide." About Arbor Surgical Technologies, Inc. Arbor Surgical Technologies, Inc., (http://www.arborsurgical.com ) with facilities in Irvine and portola Valley, CA (USA), is a privately held cardiovascular device company focused on the minimally invasive heart valve replacement market. Founded in 2002 ...

Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter

...ators. We are confident that we have developed an IVC filter that better meets the needs of implanting physicians." Crux Biomedical, headquartered in portola Valley, California, was founded in late 2004 by Dr. Thomas Fogarty and Dr. Frank Arko. The company is developing an implantable vascular device that o...